Roivant Sets $35,000 Price for LISRAYA and Launches 5 Weeks Early
ROIV has more than doubled off its 52-week low of $11.85.
Summary
Roivant priced LISRAYA at $35,000 per 30-count bottle and launched the drug commercially about five weeks ahead of schedule, adding commercial detail to yesterday's FDA approval.
Key Events · Product Development and Regulatory · ROIV
-
LISRAYA Priced at $35,000
The first disclosed pricing for the newly approved dermatomyositis therapy sets the wholesale acquisition cost at $35,000 for a 30-count bottle of 30 mg tablets.
-
Commercial Launch 5 Weeks Early
LISRAYA is commercially available as of August 28, 2026, ahead of prior guidance for a launch by end of September 2026. Prescribing is open, the specialty pharmacy network is live, and patient support is active.
-
First Targeted DM Therapy
LISRAYA is the first targeted therapy, first once-daily oral therapy, and first TYK2/JAK1 inhibitor approved for dermatomyositis, with a broad label covering adults with any disease severity.
-
Multi-Indication Pipeline
Three additional pivotal datasets are expected over the next 36 months: non-infectious uveitis topline data in 2H 2026, cutaneous sarcoidosis Phase 3 ongoing, and lichen planopilaris Phase 2b/3 initiated.
Analysis · ROIV · Life Sciences
Investors now have their first concrete look at the commercial economics of LISRAYA, the first-ever targeted therapy for dermatomyositis, after Roivant disclosed a wholesale acquisition cost of $35,000 per 30-count bottle and confirmed the drug is commercially available today — roughly five weeks ahead of its prior end-of-September launch guidance. The company estimates the U.S. market at roughly 70,000 adults. A multi-indication roadmap was also laid out, with three additional pivotal datasets expected over the next 36 months, starting with non-infectious uveitis topline data in the second half of 2026.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $34.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.1B. The 52-week trading range was $11.85 to $37.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.